The main objective of this chapter is to summarize the clinical differences found in the literature between men and women suffering from bipolar disorder. The secondary objective is to analyze the treatment and how there are gender differences in the adherence to medication. Briefly, we could say that in men the manic component predominates, both at onset and throughout their lifetime, and that they usually have comorbid drug abuse. On the other hand, women usually tend to have a predominance of depression; they have a depressive polarity both at onset and during their lifetime and experience more mixed mania episodes. Furthermore, in women onset often occurs at an older age, comorbidity of physical pathological conditions is common, and adherence to medication is greater than in men.
We cannot forget that women can experience two very important periods: pregnancy and postpartum. Both can be critical periods for the disorder, and a relapse or recurrence at either stage can have serious consequences not just for the woman but also for her baby. Because the effect of medication on the fetus still remains unclear, it makes it even more difficult to set the treatment during these periods.
- Bipolar disorder
This is a preview of subscription content, access via your institution.
Merikangas KR, Jin R, He J-P, Kessler RC, Lee S, Sampson NA, et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry. 2011;68(3):241–51.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5®). American Psychiatric Pub; 2013.
Gonzalez-Pinto A, Gutierrez M, Mosquera F, Ballesteros J, Lopez P, Ezcurra J, et al. First episode in bipolar disorder: misdiagnosis and psychotic symptoms. J Affect Disord. 1998;50(1):41–4.
López-Zurbano S, González-Pinto A, López P. Gender differences in bipolar disorder. In: Psychopathology in women. Cham: Springer; 2015. p. 641–59.
Hendrick V, Altshuler LL, Gitlin MJ, Delrahim S, Hammen C. Gender and bipolar illness. J Clin Psychiatry. 2000;61(5):393–6.. quiz 397
Popovic D, Torrent C, Goikolea JM, Cruz N, Sánchez-Moreno J, González-Pinto A, et al. Clinical implications of predominant polarity and the polarity index in bipolar disorder: a naturalistic study. Acta Psychiatr Scand. 2014;129(5):366–74.
Ketter TA. Diagnostic features, prevalence, and impact of bipolar disorder. J Clin Psychiatry. 2010;71(6):e14.
Karanti A, Bobeck C, Osterman M, Kardell M, Tidemalm D, Runeson B, et al. Gender differences in the treatment of patients with bipolar disorder: a study of 7354 patients. J Affect Disord. 2015;174:303–9.
Nivoli AMA, Pacchiarotti I, Rosa AR, Popovic D, Murru A, Valenti M, et al. Gender differences in a cohort study of 604 bipolar patients: the role of predominant polarity. J Affect Disord. 2011;133(3):443–9.
Azorin J-M, Belzeaux R, Kaladjian A, Adida M, Hantouche E, Lancrenon S, et al. Risks associated with gender differences in bipolar I disorder. J Affect Disord. 2013;151(3):1033–40.
Rasgon N, Bauer M, Glenn T, Elman S, Whybrow PC. Menstrual cycle related mood changes in women with bipolar disorder. Bipolar Disord. 2003;5(1):48–52.
Kawa I, Carter JD, Joyce PR, Doughty CJ, Frampton CM, Wells JE, et al. Gender differences in bipolar disorder: age of onset, course, comorbidity, and symptom presentation. Bipolar Disord. 2005;7(2):119–25.
Altshuler LL, Kupka RW, Hellemann G, Frye MA, Sugar CA, McElroy SL, et al. Gender and depressive symptoms in 711 patients with bipolar disorder evaluated prospectively in the Stanley Foundation bipolar treatment outcome network. Am J Psychiatry. 2010;167(6):708–15.
Saunders EFH, Fitzgerald KD, Zhang P, McInnis MG. Clinical features of bipolar disorder comorbid with anxiety disorders differ between men and women. Depress Anxiety. 2012;29(8):739–46.
Bhattacharya A, Khess CRJ, Munda SK, Bakhla AK, Praharaj SK, Kumar M. Sex difference in symptomatology of manic episode. Compr Psychiatry. 2011;52(3):288–92.
Freeman MP, Smith KW, Freeman SA, McElroy SL, Kmetz GE, Wright R, et al. The impact of reproductive events on the course of bipolar disorder in women. J Clin Psychiatry. 2002;63(4):284–7.
Drancourt N, Etain B, Lajnef M, Henry C, Raust A, Cochet B, et al. Duration of untreated bipolar disorder: missed opportunities on the long road to optimal treatment. Acta Psychiatr Scand. 2013;127(2):136–44.
Benazzi F. Gender differences in bipolar II and unipolar depressed outpatients: a 557-case study. Ann Clin Psychiatry Off J Am Acad Clin Psychiatr. 1999;11(2):55–9.
Hirschfeld RMA, Vornik LA. Recognition and diagnosis of bipolar disorder. J Clin Psychiatry. 2004;65(Suppl 15):5–9.
Goldberg JF, Ernst CL. Features associated with the delayed initiation of mood stabilizers at illness onset in bipolar disorder. J Clin Psychiatry. 2002;63(11):985–91.
Hirschfeld RMA, Lewis L, Vornik LA. Perceptions and impact of bipolar disorder: how far have we really come? Results of the national depressive and manic-depressive association 2000 survey of individuals with bipolar disorder. J Clin Psychiatry. 2003;64(2):161–74.
González-Pinto A, Aldama A, González C, Mosquera F, Arrasate M, Vieta E. Predictors of suicide in first-episode affective and nonaffective psychotic inpatients: five-year follow-up of patients from a catchment area in Vitoria. Spain J Clin Psychiatry. 2007;68(2):242–7.
Undurraga J, Baldessarini RJ, Valenti M, Pacchiarotti I, Vieta E. Suicidal risk factors in bipolar I and II disorder patients. J Clin Psychiatry. 2012;73(6):778–82.
López P, Mosquera F, de León J, Gutiérrez M, Ezcurra J, Ramírez F, et al. Suicide attempts in bipolar patients. J Clin Psychiatry. 2001;62(12):963–6.
Perris C. A study of bipolar (manic-depressive) and unipolar recurrent depressive psychoses. Introduction Acta Psychiatr Scand Suppl. 1966;194:9–14.
Coryell W, Endicott J, Keller M. Rapidly cycling affective disorder. Demographics, diagnosis, family history, and course. Arch Gen Psychiatry. 1992;49(2):126–31.
Rasgon N, Bauer M, Grof P, Gyulai L, Elman S, Glenn T, et al. Sex-specific self-reported mood changes by patients with bipolar disorder. J Psychiatr Res. 2005;39(1):77–83.
Burt VK, Rasgon N. Special considerations in treating bipolar disorder in women. Bipolar Disord. 2004;6(1):2–13.
Altshuler LL, Post RM, Leverich GS, Mikalauskas K, Rosoff A, Ackerman L. Antidepressant-induced mania and cycle acceleration: a controversy revisited. Am J Psychiatry. 1995;152(8):1130–8.
Lee S, Tsang A, Kessler RC, Jin R, Sampson N, Andrade L, et al. Rapid-cycling bipolar disorder: cross-national community study. Br J Psychiatry J Ment Sci. 2010;196(3):217–25.
Bräunig P, Sarkar R, Effenberger S, Schoofs N, Krüger S. Gender differences in psychotic bipolar mania. Gend Med. 2009;6(2):356–61.
Delvecchio G, Ciappolino V, Perlini C, Barillari M, Ruggeri M, Altamura AC, et al. Correction to: cingulate abnormalities in bipolar disorder relate to gender and outcome: a region-based morphometry study. Eur Arch Psychiatry Clin Neurosci. 2018; https://doi.org/10.1007/s00406-018-0913-3
Gressier F, Calati R, Serretti A. 5-HTTLPR and gender differences in affective disorders: a systematic review. J Affect Disord. 2016;190:193–207.
De Almeida IB, Nardi AE, De Ornelas Maia AC, Levitan M. Estrogen and transdiagnostics: a systematic review. J Depress Anxiety. 2016;5(228):2167–1044.
Meinhard N, Kessing LV, Vinberg M. The role of estrogen in bipolar disorder, a review. Nord J Psychiatry febrero de. 2014;68(2):81–7.
Kenna HA, Jiang B, Rasgon NL. Reproductive and metabolic abnormalities associated with bipolar disorder and its treatment. Harv Rev Psychiatry. 2009;17(2):138–46.
Fellinger M, Waldhör T, Blüml V, Williams N, Vyssoki B. Influence of gender on inpatient treatment for bipolar disorder: an analysis of 60,607 hospitalisations. J Affect Disord. 2018;225:104–7.
Henry C. Lithium side-effects and predictors of hypothyroidism in patients with bipolar disorder: sex differences. J Psychiatry Neurosci JPN. 2002;27(2):104–7.
Gonzalez-Pinto A, Mosquera F, Alonso M, López P, Ramírez F, Vieta E, et al. Suicidal risk in bipolar I disorder patients and adherence to long-term lithium treatment. Bipolar Disord. 2006;8(5 Pt 2):618–24.
Colom F, Vieta E, Martínez-Arán A, Reinares M, Benabarre A, Gastó C. Clinical factors associated with treatment noncompliance in euthymic bipolar patients. J Clin Psychiatry. 2000;61(8):549–55.
Johnson RE, McFarland BH. Lithium use and discontinuation in a health maintenance organization. Am J Psychiatry. 1996;153(8):993–1000.
Vega P, Hernández M, Martinez-Cengotitabengoa M, Gonzalez I. Why do bipolar men not comply with treatment? Int Clin Psychopharmacol. 2011;26(39):63–9.
Lang K, Korn J, Muser E, Choi JC, Abouzaid S, Menzin J. Predictors of medication nonadherence and hospitalization in Medicaid patients with bipolar I disorder given long-acting or oral antipsychotics. J Med Econ. 2011;14(2):217–26.
Baldessarini RJ, Perry R, Pike J. Factors associated with treatment nonadherence among US bipolar disorder patients. Hum Psychopharmacol. 2008;23(2):95–105.
Kriegshauser K, Sajatovic M, Jenkins JH, Cassidy KA, Muzina D, Fattal O, et al. Gender differences in subjective experience and treatment of bipolar disorder. J Nerv Ment Dis. 2010;198(5):370–2.
Leskelä U, Melartin T, Rytsälä H, Jylhä P, Sokero P, Lestelä-Mielonen P, et al. Influence of personality on objective and subjective social support among patients with major depressive disorder: a prospective study. J Nerv Ment Dis. 2009;197(10):728–35.
Franzoi SL, Koehler V. Age and gender differences in body attitudes: a comparison of young and elderly adults. Int J Aging Hum Dev. 1998;47(1):1–10.
Trede K, Baldessarini RJ, Viguera AC, Bottero A. Treatise on insanity in pregnant, postpartum, and lactating women (1858) by Louis-Victor Marcé: a commentary. Harv Rev Psychiatry. 2009;17(2):157–65.
Viguera AC, Tondo L, Koukopoulos AE, Reginaldi D, Lepri B, Baldessarini RJ. Episodes of mood disorders in 2252 pregnancies and postpartum periods. Am J Psychiatry. 2011;168(11):1179–85.
Viguera AC, Whitfield T, Baldessarini RJ, Newport DJ, Stowe Z, Reminick A, et al. Risk of recurrence in women with bipolar disorder during pregnancy: prospective study of mood stabilizer discontinuation. Am J Psychiatry. 2007;164(12):1817–24; quiz 1923
Mateo MJZ, Albéniz JM, Yañez LP. uso de psicofarmacos durante el embarazo y la lactancia. 2nd ed. Osakidetza: Vitoria-Gasteiz (Álava); 2016.
Sharma V, Burt VK, Ritchie HL. Bipolar II postpartum depression: Detection, diagnosis, and treatment. Am J Psychiatry. 2009;166(11):1217–21.
Jones I, Chandra PS, Dazzan P, Howard LM. Bipolar disorder, affective psychosis, and schizophrenia in pregnancy and the post-partum period. Lancet Lond Engl. 2014;384(9956):1789–99.
Heron J, Haque S, Oyebode F, Craddock N, Jones I. A longitudinal study of hypomania and depression symptoms in pregnancy and the postpartum period. Bipolar Disord. 2009;11(4):410–7.
Sharma V, Khan M, Corpse C, Sharma P. Missed bipolarity and psychiatric comorbidity in women with postpartum depression. Bipolar Disord. 2008;10(6):742–7.
Angus-Leppan H, Liu RSN. Weighing the risks of valproate in women who could become pregnant. BMJ. 2018;361:k1596.
National Institute for Health and Care Excellence. NICE. Bipolar disorder: assessment and management. 2014.
Jauhar S, McKenna PJ, Laws KR. NICE guidance on psychological treatments for bipolar disorder: searching for the evidence. Lancet Psychiatry. 2016;3(4):386–8.
Bodén R, Lundgren M, Brandt L, Reutfors J, Andersen M, Kieler H. Risks of adverse pregnancy and birth outcomes in women treated or not treated with mood stabilisers for bipolar disorder: population based cohort study. BMJ. 2012;345:e7085.
National Institute for Health and Care Excellence. NICE. Antenatal and postnatal mental health: clinical management and service guidance. In: NICE. 2014.
Payne JL, Meltzer-Brody S. Antidepressant use during pregnancy: current controversies and treatment strategies. Clin Obstet Gynecol. 2009;52(3):469–82.
Álamo C, Alonso Z, Alvarez I. In: salazar M, Peral C, Pastor FJ, editors. Manejo de psicofármacos en situaciones vitales específicas. Manual de Psicofarmacología. Madrid: Editoral Médica Panamericana; 2011. p. 87–92.
Einarson A, Boskovic R. Use and safety of antipsychotic drugs during pregnancy. J Psychiatr Pract. 2009;15(3):183–92.
ACOG Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation. Obstet Gynecol. 2008;111(4):1001–20.
Chisolm MS, Payne JL. Management of psychotropic drugs during pregnancy. BMJ. 2016;532:h5918.
Gentile S. Lithium in pregnancy: the need to treat, the duty to ensure safety. Expert Opin Drug Saf. 2012;11(3):425–37.
arcía-Esteve LL (último), Valdés Miyar. Manual de Psiquiatría perinatal. Guía para el manejo de los trastornos mentales durante el embarazo, posparto y lactancia. Madrid: Médica Panamerican; 2016.
Coughlin CG, Blackwell KA, Bartley C, Hay M, Yonkers KA, Bloch MH. Obstetric and neonatal outcomes after antipsychotic medication exposure in pregnancy. Obstet Gynecol. 2015;125(5):1224–35.
Gentile S. Drug treatment for mood disorders in pregnancy. Curr Opin Psychiatry. 2011;24(1):34–40.
Cohen LS, Friedman JM, Jefferson JW, Johnson EM, Weiner ML. A reevaluation of risk of in utero exposure to lithium. JAMA. 1994;271(2):146–50.
McKnight RF, Adida M, Budge K, Stockton S, Goodwin GM, Geddes JR. Lithium toxicity profile: a systematic review and meta-analysis. Lancet Lond Engl. 2012;379(9817):721–8.
Gentile S. Prophylactic treatment of bipolar disorder in pregnancy and breastfeeding: focus on emerging mood stabilizers. Bipolar Disord. 2006;8(3):207–20.
Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Perucca E, et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurol. 2018;17(6):530–8.
Holmes LB, Mittendorf R, Shen A, Smith CR, Hernandez-Diaz S. Fetal effects of anticonvulsant polytherapies: different risks from different drug combinations. Arch Neurol. 2011;68(10):1275–81.
Elkjær LS, Bech BH, Sun Y, Laursen TM, Christensen J. Association between prenatal valproate exposure and performance on standardized language and mathematics tests in school-aged children. JAMA Neurol. 2018;75(6):663–71.
Kälviäinen R, Straus S, Dogne J-M, Bakchine S, Haas M. Reducing valproate use in women with epilepsy. Lancet Neurol. 2018;17(7):580–1.
Wieck A, Jones S. Dangers of valproate in pregnancy. BMJ. 2018;361:k1609.
FDA, US. FDA Drug Safety Communication: valproate anti-seizure products contraindicated for migraine prevention in pregnant women due to decreased IQ scores in exposed children. FDA website; 2018.
European Medicines Agency. PRAC recommends new measures to avoid valproate exposure in pregnancy [Internet]. 2018. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2018/02/news_detail_002903.jsp&mid=WC0b01ac058004d5c1.
National Collaborating Centre for Mental Health. Antenatal and postnatal mental health: the NICE guideline on clinical management and service guidance. British Psychological Society; 2007.
Dolk H, Jentink J, Loane M, Morris J, de Jong-van den Berg LTW, EUROCAT Antiepileptic Drug Working Group. Does lamotrigine use in pregnancy increase orofacial cleft risk relative to other malformations? Neurology. 2008;71(10):714–22.
Huybrechts KF, Hernández-Díaz S, Patorno E, Desai RJ, Mogun H, Dejene SZ, et al. Antipsychotic use in pregnancy and the risk for congenital malformations. JAMA Psychiatry. 2016;73(9):938–46.
Food and Drug Administration. FDA Drug Safety Communication: Antipsychotic drug labels updated on use during pregnancy and risk of abnormal muscle movements and withdrawal symptoms in newborns [Internet]. 2011. http://www.fda.gov/Drugs/DrugSafety/ucm243903.
Gentile S. Antipsychotic therapy during early and late pregnancy. A systematic review. Schizophr Bull. 2010;36(3):518–44.
Mehta TM, Van Lieshout RJ. A review of the safety of clozapine during pregnancy and lactation. Arch Womens Ment Health. 2017;20(1):1–9.
Gentile S, Bellantuono C. Selective serotonin reuptake inhibitor exposure during early pregnancy and the risk of fetal major malformations: focus on paroxetine. J Clin Psychiatry. 2009;70(3):414–22.
Sujan AC, Rickert ME, Öberg AS, Quinn PD, Hernández-Díaz S, Almqvist C, et al. Associations of maternal antidepressant use during the first trimester of pregnancy with preterm birth, small for gestational age, autism spectrum disorder, and attention-deficit/hyperactivity disorder in offspring. JAMA. 2017;317(15):1553–62.
Nordeng H, Spigset O. Treatment with selective serotonin reuptake inhibitors in the third trimester of pregnancy: effects on the infant. Drug Saf. 2005;28(7):565–81.
Chambers CD, Hernandez-Diaz S, Van Marter LJ, Werler MM, Louik C, Jones KL, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med. 2006;354(6):579–87.
Brown HK, Ray JG, Wilton AS, Lunsky Y, Gomes T, Vigod SN. Association between serotonergic antidepressant use during pregnancy and autism spectrum disorder in children. JAMA. 2017;317(15):1544–52.
Healy D, Le Noury J, Mangin D. Links between serotonin reuptake inhibition during pregnancy and neurodevelopmental delay/spectrum disorders: a systematic review of epidemiological and physiological evidence. Int J Risk Saf Med. 2016;28(3):125–41.
Enato E, Moretti M, Koren G. The fetal safety of benzodiazepines: an updated meta-analysis. J Obstet Gynaecol Can. 2011;33(1):46–8.
Rasmussen K. The practice of electroconvulsive therapy: recommendations for treatment, training, and privileging (second edition). J ECT. 2002;18(1):58–9.
Yonkers KA, Vigod S, Ross LE. Diagnosis, pathophysiology, and management of mood disorders in pregnant and postpartum women. Obstet Gynecol. 2011;117(4):961–77.
Editors and Affiliations
Rights and permissions
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
López-Zurbano, S., González-Pinto, A. (2019). Gender Differences in Bipolar Disorder. In: Sáenz-Herrero, M. (eds) Psychopathology in Women. Springer, Cham. https://doi.org/10.1007/978-3-030-15179-9_31
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-15178-2
Online ISBN: 978-3-030-15179-9
eBook Packages: MedicineMedicine (R0)